Last reviewed · How we verify
NCT05123001
Wearable Sensors and Molecular Omics to Detect and Mitigate Cell Therapy Adverse Events
trial in Hodgkin Lymphoma in 11 participants. Completed in 7 July 2022.
7 July 2022
Quick facts
| Lead sponsor | Stanford University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 11 |
| Start date | 15 July 2021 |
| Primary completion | 7 July 2022 |
| Estimated completion | 7 July 2022 |
| Sites | 1 location across United States |
Conditions studied
- Hodgkin Lymphoma — all drugs for Hodgkin Lymphoma →
- Non Hodgkin Lymphoma — all drugs for Non Hodgkin Lymphoma →
- Leukemia — all drugs for Leukemia →
- Multiple Myeloma — all drugs for Multiple Myeloma →
Sponsor
Stanford University
Who can join
18 and older, any sex, with Hodgkin Lymphoma or Non Hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to monitor physiological and molecular changes during and following CAR-T cancer cell therapy, towards improved management of adverse events including Cytokine Release Syndrome and neurotoxicity. Our study aims are to improved early detection and precise management of adverse events for patients receiving Chimeric antigen receptor T- cell (CAR-T): 1. To assess the feasibility, including accuracy, usability, and usefulness of wearable sensors in CAR-T patients. 2. To generate comprehensive multiomic profile analysis following CAR-T therapy. 3. To perform integrated analysis of wearables sensor data, omics data, and symptom/clinical data.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Focusing on toxicity management: Challenges and strategies for HER2-targeted antibody-drug conjugates in breast cancer.
Liu X, Yin S, Li X, Nie J. · · 2026 · PMID 41785741 · DOI 10.1016/j.breast.2026.104741
Verify or expand the search:
- PubMed search for NCT05123001
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hodgkin Lymphoma
Currently open trials in the same condition.
- NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
- NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
- NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
- NCT06176690 — Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas · Phase 1 · recruiting
- NCT07002216 — BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma · Phase 2 · recruiting
Other Stanford University trials
Trials by the same sponsor.
- NCT05945147 — Ketamine and Midazolam Infusions for CRPS: Feasibility Study · Phase 2 · withdrawn
- NCT04225949 — Patients Understanding of PROM Graphs · NA · withdrawn
- NCT06273098 — School-Based Bladder Health Intervention · NA · withdrawn
- NCT04652635 — Management of Nailbed Injuries · NA · withdrawn
- NCT05443503 — Stanford Spine Keeper - Managing Your Low Back Pain · NA · suspended
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05123001 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Stanford University
- Last refreshed: 29 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05123001.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing